MD Anderson researchers validated LFSPRO, a mathematical model designed to improve identification of individuals at elevated risk for Li-Fraumeni syndrome by integrating genetic and clinical risk factors. Li-Fraumeni syndrome is driven by TP53 mutations and confers high lifetime cancer risk, making accurate risk stratification important for prevention and surveillance decisions. The work focused on enhancing prediction beyond existing approaches, and the validated tool aims to support clinicians in distinguishing likely high-risk carriers from those with lower probability. As hereditary cancer management shifts toward earlier and more personalized surveillance, risk scoring tools increasingly determine how patients move into genetic testing and intervention pathways. The model’s clinical utility will likely depend on uptake in genetic counseling settings and how it performs across different populations, but MD Anderson’s validation effort positions LFSPRO as a candidate to influence real-world referral patterns for TP53-related screening.